CD274 and renal cell carcinoma: A phase 1 trial of 42 patients with advanced cancers (melanoma, NSCLC, colorectal, RCC and prostate cancers) treated with ICIs showed a response rate of 36% for patients positive for PD-L1 expression vs. 0% if PD-L1 expression was negative.